Medical/Pharmaceuticals
Innovative Collaboration: Buzzreach and Oncoshot Spearhead Clinical Trial Advancements in Japan
SINGAPORE, Sept. 14, 2023 /PRNewswire/ -- Buzzreach and Oncoshot, two prominent entities in the clinical trials domain, have announced an impactful collaboration to accelerate clinical trials inJapan. The former specialises in clinical trial site recruitment and retention and project managemen...
2023-09-14 10:00
2521
Avasa raises $1.55M in oversubscribed funding round with innovative implantable devices
MIAMI and AUCKLAND, New Zealand, Sept. 14, 2023 /PRNewswire/ -- Avasa, a medical device pioneer advancing surgical techniques for improved patient outcomes, announces the successful completion of its recent funding, raising an impressive$1.55 million in capital investment. The influx of new inves...
2023-09-14 04:50
1974
AWAK TECHNOLOGIES RAISES US$20+ MILLION, READYING ITS WEARABLE DIALYSIS DEVICE FOR US-BASED PIVOTAL TRIAL
* AWAK closes one of the largest MedTech fundraise in 2023 in Southeast Asia * The Series B round was co-led by new investor Lion X Ventures and long-term investor Vickers Venture Partners, along with other new and existing investors * AWAK's ultra-portable peritoneal dialysis system enables ...
2023-09-13 21:27
2466
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine's artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models — — In May 2023, the U.S. Food and Drug Administration (FDA) cleared Insilico's I...
2023-09-13 20:29
1941
Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets
SINGAPORE, Sept. 13, 2023 /PRNewswire/ -- Menarini Asia-Pacific has entered into a long-term exclusive licensing partnership with Astellas Pharma Inc. (Astellas) for the development, manufacturing and commercialization of the orally administered Janus kinase (JAK) inhibitor Smyraf® 50 mg and 100 ...
2023-09-13 10:30
2589
Maxigen Biotech Inc. Wins 2023 Asia's Leading SMEs Award for Innovative Sustainability
KUALA LUMPUR, Malaysia, Sept. 13, 2023 /PRNewswire/ -- Maxigen Biotech
Inc.(MBI), a pioneering biotech company headquartered inTaiwan, has been
honored with the prestigious 2023 Asia's Leading SMEs Award by ACES
underscoring its commitment to innovation and sustainable operations.
2023-09-13 09:30
2128
Frost & Sullivan Recognizes Suki AI with the 2023 North American Technology Leadership Award
Suki's innovative AI Assistant brings the power of Generative AI to health systems and delivers strong ROI SAN ANTONIO, Sept. 12, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the healthcare voice assistant industry and, based on its findings, recognizesSuki AI with the 2023 North Am...
2023-09-12 22:00
1833
TMRW Life Sciences Receives CE Mark for the CryoRobot Select, its Next-Generation Automated Platform to Safely Manage and Store Frozen Eggs and Embryos
TMRW's Cutting-Edge Technology is Raising the Standard of Care in Global Fertility NEW YORK, Sept. 12, 2023 /PRNewswire/ -- TMRW Life Sciences, a fertility technology company automating the IVF lab, today announced that it has received a CE Mark for the CryoRobot Select (CRS). The European desig...
2023-09-12 21:01
1722
CSafe Expands Executive Team with Chief Financial Officer
Seasoned financial leader, Anthony Pishotti, joins CSafe executive team to further drive the company's portfolio and geographic growth. MONROE, Ohio, Sept. 12, 2023 /PRNewswire/ -- CSafe, the largest active and passive temperature-controlled shipping solutions provider for the biopharmaceutical ...
2023-09-12 20:59
2170
Pierre Fabre Laboratories Acquires Vertical Bio and its Innovative Targeted Therapy Candidate for Patients Suffering From Non-Small Cell Lung Cancer With MET Alteration
CASTRES, France and BASEL, Switzerland, Sept. 12, 2023 /PRNewswire/ --
Pierre Fabre Laboratories
2023-09-12 20:00
1537
New South Wales Government (NSW) Partner, Myeloid Therapeutics, Initiates Patient Dosing with MT-302 in Phase 1 Study at Clinical Site in Australia
NSW and Myeloid entered into a partnership in February 2023 to launch state-of-the-art GMP manufacturing RNA facility CAMBRIDGE, Mass., Sept. 12, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage oncology company, has dosed the first patient with MT-302 in a Phase 1 s...
2023-09-12 20:00
1090
Metabolon Launches New Biological Stress Discovery Panel to Aid Detection of Inflammation and Biological Stress Biomarkers
Metabolon's new Biological Stress Discovery Panel supports inflammation, immune function, and stress research with advanced analytics MORRISVILLE, N.C., Sept. 12, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of research, di...
2023-09-12 19:57
1152
The Korean Society of Ginseng confirms the effects of consuming red ginseng in the prevention and improvement of dementia
- Through the study "Elucidation of Mechanisms for Dementia Prevention and Improvement by Red Ginseng" SEOUL, South Korea, Sept. 12, 2023 /PRNewswire/ -- Through continuous research, the secrets of ginseng, a representative medicinal herb of Korea, are being revealed, showcasing its efficacy. Re...
2023-09-12 17:00
2060
Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening
* Lunit's collaborative study supports AI as a viable alternative to one human reader inEurope's double reading system - published in The Lancet Digital Health SEOUL, South Korea, Sept. 12, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagno...
2023-09-12 13:03
2156
MGI Launches the DCS Lab Initiative to Expand Global Omics Access and Capabilities
SHENZHEN, China, Sept. 11, 2023 /PRNewswire/ -- MGI, a company committed to building core tools and technology to lead life science, today announced the DCS Lab Initiative to help facilitate large-scale leading multi-omics laboratories and spur critical scientific research. Under the initiative, ...
2023-09-11 19:43
1173
IPMG Drives Health Transformation and Strengthens Indonesia's Economy Through Efforts to Accelerate Access to Innovative Medicines and Vaccines, also Partnerships
JAKARTA, Indonesia, Sept. 11, 2023 /PRNewswire/ -- The research and development-based multinational pharmaceutical industry association, the International Pharmaceutical Manufacturers Group (IPMG) is always committed to supporting and encouraging advocacy and transformation of Government policie...
2023-09-11 18:52
2081
Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer
AMSTERDAM, Sept. 11, 2023 /PRNewswire/ -- Norgine, a leading European specialist pharmaceutical company dedicated to improving the lives of patients, is pleased to announce the appointment ofSaulo Martiniano as its new Chief Operating Officer (COO). Saulo joins Norgine with a wealth of experience...
2023-09-11 15:00
1349
Can we really make a difference in reducing the heartbreak of millions of miscarriages each year?
ADELAIDE, Australia, Sept. 11, 2023 /PRNewswire/ -- Globally, one in six pregnancies end in miscarriage, which is generally defined as the loss of an intrauterine pregnancy before viability. This equates to an estimated 23 million miscarriages every year, or over 40 miscarriages per minute. Th...
2023-09-11 14:58
1612
Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors
SINGAPORE, Sept. 11, 2023 /PRNewswire/ -- On September 9th, 2023, Biosyngen Pte Ltd (hereafter as "Biosyngen") announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for Phase I/II clinical trial ofBRL03 for the treatment of lung cancer, gastric cancer and other ad...
2023-09-11 14:53
1466
PeproMene Bio, Inc. Announced Completion of the First Dose Cohort and Opening of the Second Dose Cohort in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells)
IRVINE, Calif., Sept. 11, 2023 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first dose cohort of its phase 1 relapsed or refractory B-cell Non-Hodgkin Lymphoma (r/r B-NHL) clinical ...
2023-09-11 12:05
2236
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8005
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7400